Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1079) 1079
Newsletter (66) 66
Publication (65) 65
Newspaper Article (20) 20
Book Review (15) 15
Magazine Article (9) 9
Book Chapter (8) 8
Dissertation (4) 4
Web Resource (2) 2
Conference Proceeding (1) 1
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
aprepitant (1001) 1001
humans (560) 560
index medicus (519) 519
nausea (426) 426
chemotherapy (415) 415
oncology (415) 415
cancer (368) 368
prevention (349) 349
double-blind (343) 343
female (341) 341
vomiting (316) 316
male (308) 308
vomiting - chemically induced (299) 299
nausea - chemically induced (291) 291
middle aged (279) 279
antiemetics - therapeutic use (271) 271
dexamethasone (253) 253
adult (244) 244
placebo-controlled trial (228) 228
vomiting - prevention & control (220) 220
antineoplastic agents - adverse effects (215) 215
nausea - prevention & control (206) 206
aged (203) 203
pharmacology & pharmacy (202) 202
morpholines - therapeutic use (185) 185
palonosetron (172) 172
medicine & public health (170) 170
moderately emetogenic chemotherapy (170) 170
research (161) 161
chemotherapy-induced nausea (160) 160
antagonist aprepitant (159) 159
chemotherapy-induced nausea and vomiting (151) 151
efficacy (143) 143
ondansetron (138) 138
high-dose cisplatin (135) 135
neoplasms - drug therapy (135) 135
antiemetics (134) 134
care and treatment (128) 128
health care sciences & services (124) 124
antiemetics - administration & dosage (116) 116
nausea - drug therapy (116) 116
vomiting - drug therapy (116) 116
cisplatin (115) 115
treatment outcome (113) 113
nursing (112) 112
analysis (110) 110
morpholines - administration & dosage (110) 110
neurokinin-1 receptor antagonists (109) 109
rehabilitation (109) 109
complications and side effects (105) 105
pain medicine (100) 100
double-blind method (99) 99
induced nausea (96) 96
drug therapy (95) 95
drug therapy, combination (95) 95
emesis (94) 94
rehabilitation medicine (91) 91
receptor antagonist (90) 90
health aspects (89) 89
gastrointestinal agents (87) 87
antineoplastic combined chemotherapy protocols - adverse effects (86) 86
morpholines - pharmacology (86) 86
cinv (85) 85
dexamethasone - therapeutic use (83) 83
dosage and administration (82) 82
risk factors (79) 79
animals (78) 78
pharmacokinetics (78) 78
substance p (78) 78
cisplatin-induced emesis (75) 75
prospective studies (73) 73
fosaprepitant (71) 71
cisplatin - adverse effects (69) 69
dexamethasone - administration & dosage (68) 68
patients (68) 68
phase-iii (67) 67
cancer therapies (66) 66
substance-p (66) 66
antiemetics - adverse effects (65) 65
antineoplastic agents - therapeutic use (65) 65
clinical trials (65) 65
antineoplastic combined chemotherapy protocols - therapeutic use (64) 64
cancer patients (64) 64
receptor antagonist aprepitant (64) 64
young adult (64) 64
delayed emesis (62) 62
prophylaxis (62) 62
antiemetic (61) 61
antiemetics - pharmacology (61) 61
morpholines - adverse effects (60) 60
nursing management/nursing research (60) 60
therapy (60) 60
granisetron (59) 59
aged, 80 and over (58) 58
quality of life (55) 55
olanzapine (54) 54
safety (53) 53
adolescent (51) 51
breast cancer (51) 51
induced emesis (51) 51
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1133) 1133
German (12) 12
Japanese (9) 9
French (8) 8
Spanish (6) 6
Korean (4) 4
Czech (2) 2
Russian (2) 2
Chinese (1) 1
Hungarian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Aprepitant Has Mixed Effects on Nausea and Reduces Other Symptoms in Patients With Gastroparesis and Related Disorders
by Pasricha, Pankaj J and Pasricha, Pankaj Jay and Yates, Katherine P and Sarosiek, Irene and McCallum, Richard W and Abell, Thomas L and Koch, Kenneth L and Nguyen, Linda Anh B and Snape, William J and Hasler, William L and Clarke, John O and Dhalla, Sameer and Stein, Ellen M and Stein, Ellen and Lee, Candice and Lee, Linda A and Miriel, Laura and Miriel, Laura A and Van Natta, Mark L and Van Natta, Mark and Grover, Madhusudan and Farrugia, Gianrico and Tonascia, James and Hamilton, Frank and Hamilton, Frank A and Parkman, Henry P and DeVole, Nata and Earle, Karen and Kirkeby, Kjersti and Lin, Mimi and Ponting, Katie and Yee, Gloria and Kim, Yale and Garay, Gotzone and Orlando, Chiara and Mauer, Alan and Orthey, Perry and Palit, Amiya and Connery, Sean and Gomez, Yvette and Romero, Roberta and Vega, Natalia and Alvarado, Ben and Hatter, Lisa and Howard, Ronna and Nowotny, Lindsay and Herman, William and Kraftson, Andrew and Rothberg, Amy E and Wootten, Sophanara and Baxter, Lynn and Brown, Anya and Stuart, Paula and Culler, Samantha and Bernard, Cheryl and Serrano, Jose and James, Stephen and Torrance, Rebecca and Hall, Sherry and Belt, Patricia and Dodge, John and Donithan, Michele and Hallinan, Erin and Isaacson, Milana and May, Patrick K and Sternberg, Alice and Wagoner, Annette and Wilson, Laura and NIDDK Gastroparesis Clinical Res and NIDDK Gastroparesis Clinical Research Consortium (GpCRC)
Gastroenterology, ISSN 0016-5085, 01/2018, Volume 154, Issue 1, pp. 65 - 76.e11
There are few effective treatments for nausea and other symptoms in patients with gastroparesis and related syndromes. We performed a randomized trial of the... 
RCT | Chronic Nausea and Vomiting | Gastroparesis | Aprepitant Treatment | NK1 ANTAGONIST | EMETOGENIC CHEMOTHERAPY | ANTAGONIST APREPITANT | CHEMOTHERAPY-INDUCED NAUSEA | RECEPTOR ANTAGONISTS | GASTRIC ELECTRICAL-STIMULATION | PREVENTION | IDIOPATHIC GASTROPARESIS | DOUBLE-BLIND | SUBSTANCE-P | GASTROENTEROLOGY & HEPATOLOGY | Aprepitant | Double-Blind Method | Humans | Middle Aged | Gastroparesis - complications | Male | Treatment Outcome | Nausea - prevention & control | Nausea - etiology | Antiemetics - therapeutic use | Vomiting - etiology | Adult | Female | Chronic Disease | Vomiting - prevention & control | Morpholines - therapeutic use | Care and treatment | Analysis | Nausea | chronic nausea and vomiting | aprepitant treatment
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Curative Effect of Aprepitant Preventing CINV
by Guan, Shasha and Zhang, Lisha and Zhong, Diansheng and Zhong, Diansheng and Ma, Qing and Meng, Fanlu and Shao, Yi and Shao, Yi and Yu, Tao and Liu, Xia
Chinese Journal of Lung Cancer, ISSN 1009-3419, 2018, Volume 21, Issue 10, pp. 800 - 804
Aprepitant | CINV | Cisplatin | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Aprepitant
American Journal of Health-System Pharmacy, ISSN 1079-2082, 12/2017, Volume 74, Issue 24, p. 2026
Aprepitant | Product introduction | Pharmaceutical industry
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text A phase II open-label study of aprepitant as anti-emetic prophylaxis in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy
by Brandwein, Joseph M and Seki, Jack T and Atenafu, Eshetu G and Rostom, Amr and Lutynski, Andrzej and Rydlewski, Anna and Schimmer, Aaron D and Schuh, Andre C and Gupta, Vikas and Yee, Karen W. L
Supportive Care in Cancer, ISSN 0941-4355, 2018, Volume 27, Issue 6, pp. 2295 - 2300
Despite the widespread use of 5-HT3 antagonists as anti-emetic prophylaxis in patients with acute myeloid leukemia (AML) receiving induction chemotherapy,... 
Chemotherapy | Neurokinin inhibitors | Acute myeloid leukemia | Anti-emetics | INDUCED NAUSEA | DEXAMETHASONE | EFFICACY | NEUROKININ-1 ANTAGONIST APREPITANT | PREVENTION | CANCER | RECEPTOR ANTAGONIST | CISPLATIN | ONCOLOGY | HEALTH CARE SCIENCES & SERVICES | DOUBLE-BLIND | REHABILITATION | PLACEBO-CONTROLLED TRIAL | Prospective Studies | Leukemia, Myeloid, Acute - pathology | Humans | Middle Aged | Induction Chemotherapy - methods | Male | Antiemetics - therapeutic use | Leukemia, Myeloid, Acute - drug therapy | Female | Aged | Retrospective Studies | Aprepitant - therapeutic use | Antiemetics - pharmacology | Aprepitant - pharmacology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens 11 Medical and Health Sciences 1117 Public Health and Health Services
by Yoshida, Naohisa and Taguchi, Tetsuya and Nakanishi, Masayoshi and Inoue, Ken and Okayama, Tetsuya and Ishikawa, Takeshi and Otsuji, Eigo and Takayama, Koichi and Kuroboshi, Haruo and Kanazawa, Motohiro and Itoh, Yoshito
BMC Pharmacology and Toxicology, 01/2019, Volume 20, Issue 1
Aprepitant | Chemotherapy | MEC | Nausea | Palonosetron
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text It all begins with a promise
by Kelkar, Dhananjay
Indian Journal of Medical and Paediatric Oncology, ISSN 0971-5851, 04/2019, Volume 40, Issue 2, pp. 279 - 281
Once you decide to walk on an adventurous path, you need to follow the process stated below: ·Make a resolve ·Seek guidance ·Practice ·Final preparation for... 
Aprepitant | Coronary artery bypass | Marathons
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Study of the efficacy of aprepitant in FOLFOX/FOLFIRI for elderly patients with advanced colorectal cancer
by Hanaka, Junichi and Takahashi, Misaki and Nakayama, Hiromichi and Terashima, Teruaki
Japanese Journal of Cancer and Chemotherapy, ISSN 0385-0684, 05/2016, Volume 43, Issue 5, pp. 583 - 586
Aprepitant | FOLFOX | FOLFIRI
Journal Article
Details down arrow
8. Full Text ATC/DDD classification
WHO Drug Information, ISSN 1010-9609, 09/2018, Volume 32, Issue 4, p. 556
Aprepitant | Hydrochlorothiazide | Dapagliflozin | Saxagliptin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-κB axis: Shedding new light on resistance to Aprepitant
by Bashash, Davood and Safaroghli-Azar, Ava and Bayati, Samaneh and Razani, Elham and Pourbagheri-Sigaroodi, Atieh and Gharehbaghian, Arshia and Momeny, Majid and Sanjadi, Maryam and Rezaie-Tavirani, Mostafa and Ghaffari, Seyed H
International Journal of Biochemistry and Cell Biology, ISSN 1357-2725, 10/2018, Volume 103, pp. 105 - 114
While a batch of efforts are fastened on synthesizing the novel targeted anti-cancer agents, recent investigations have achieved a breakthrough in identifying... 
Aprepitant | Acute leukemia | NF-κB | Arsenic trioxide | Neurokinin-1 receptor | LYMPHOBLASTIC-LEUKEMIA CELLS | APOPTOSIS | ANTAGONIST APREPITANT | CHEMOTHERAPY-INDUCED NAUSEA | MECHANISM | BIOCHEMISTRY & MOLECULAR BIOLOGY | NK-1 RECEPTOR | C-MYC | DEATH | CANCER | CELL BIOLOGY | NF-kappa B | SUBSTANCE-P
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Effectiveness and safety of combined neurokinin-1 antagonist aprepitant treatment for multiple-day anthracycline-induced nausea and vomiting
by Li, Quanfu and Wu, Yungaowa and Wang, Wenjuan and Deng, Shuqin and Jiang, Caihong and Chen, Feng and Zhao, Jun and Li, Hui and Bai, Xiaojun and Hou, Jixiang and Da, Lenggaowa and Zhao, Lanzhen and Gao, Jiali and Jin, Gaowa
Current Problems in Cancer, ISSN 0147-0272, 2019, p. 100462
Objective: To assess the safety and efficacy of combined neurokinin-1 antagonist aprepitant treatment for multiple-day anthracycline chemotherapy-induced... 
Aprepitant | CINV | Anthracycline | Multiple-day chemotherapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Assessment of Drug-Drug Interaction between Warfarin and Aprepitant and Its Effects on PT-INR of Patients Receiving Anticancer Chemotherapy
by Junpei Takakia and Yoshiyuki Ohnoa and Maiko Yamadaa and Ryo Yamaguchia and Akihiro Hisakab and Hiroshi Suzukia and Faculty of Medicine and aDepartment of Pharmacy and The University of Tokyo Hospital and The University of Tokyo and Graduate School of Pharmaceutical Sciences and Chiba University and bDepartment of Clinical Pharmacology and Pharmacometrics
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2016, Volume 39, Issue 5, pp. 863 - 868
Aprepitant is a known inducer of CYP2C9, the main warfarin-metabolizing enzyme. Consequently, co-administration of these two drugs may result in reduction of... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant
by Bergström, Mats and Hargreaves, Richard J and Burns, H.Donald and Goldberg, Michael R and Sciberras, David and Reines, Scott A and Petty, Kevin J and Ögren, Mattias and Antoni, Gunnar and Långström, Bengt and Eskola, Olli and Scheinin, Mika and Solin, Olof and Majumdar, Anup K and Constanzer, Marvin L and Battisti, Wendy P and Bradstreet, Thomas E and Gargano, Cynthia and Hietala, Jarmo
Biological Psychiatry, ISSN 0006-3223, 2004, Volume 55, Issue 10, pp. 1007 - 1012
Background Aprepitant is a highly selective substance P (neurokinin 1 [NK ] receptor) antagonist that significantly improves the pharmacotherapy of acute and... 
Substance P | neurokinin 1 receptor (NK 1), aprepitant | depression | aprepitant | neurokinin 1 receptor (NK | LIVING HUMAN-BRAIN | neurokinin 1 receptor (NK1) | ANTAGONIST APREPITANT | CONTROLLED TRIAL | CHEMOTHERAPY-INDUCED NAUSEA | RAT | PSYCHIATRY | PREVENTION | NEUROSCIENCES | NK1 | substance P | CISPLATIN-INDUCED EMESIS | STRIATUM | SUBSTANCE-P RECEPTORS | Single-Blind Method | Brain - diagnostic imaging | Iodine Radioisotopes | Humans | Morpholines - pharmacology | Male | Morpholines - blood | Tomography, Emission-Computed - methods | Brain - metabolism | Dose-Response Relationship, Drug | Receptors, Neurokinin-1 - chemistry | Brain Mapping | Adult | Receptors, Neurokinin-1 - metabolism | Binding Sites | Neurokinin-1 Receptor Antagonists
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Response to "Aprepitant and fosaprepitant decrease the effectiveness of hormonal contraceptives
by Patel, P and Leeder, JS and Piquette-Miller, M and Dupuis, LL
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, ISSN 0306-5251, 03/2018, Volume 84, Issue 3, pp. 604 - 604
aprepitant | drug-drug interactions | PHARMACOLOGY & PHARMACY | fosaprepitant
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text In vitro and in vivo pharmacological characterization of the novel NK 1 receptor selective antagonist Netupitant
by Rizzi, Anna and Campi, Barbara and Camarda, Valeria and Molinari, Stefano and Cantoreggi, Sergio and Regoli, Domenico and Pietra, Claudio and Calo', Girolamo
Peptides, ISSN 0196-9781, 09/2012, Volume 37, Issue 1, pp. 86 - 97
The novel NK receptor ligand Netupitant has been characterized in vitro and in vivo. In calcium mobilization studies CHO cells expressing the human NK... 
Aprepitant | Calcium mobilization | Guinea pig ileum | Gerbils | Mice | Netupitant
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Assessment of drug-drug interaction between warfarin and aprepitant and its effects on PT-INR of patients receiving anticancer chemotherapy
by Takaki, Junpei and Ohno, Yoshiyuki and Yamada, Maiko and Yamaguchi, Ryo and Hisaka, Akihiro and Suzuki, Hiroshi
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2016
Aprepitant is a known inducer of CYP2C9, the main warfarin-metabolizing enzyme. Consequently, co-administration of these two drugs may result in reduction of... 
CYP2C9 | aprepitant | drug-drug interaction | chemotherapy | warfarin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Inhibition of tachykinin NK1receptor using aprepitant induces apoptotic cell death and G1 arrest through Akt/p53 axis in pre-B acute lymphoblastic leukemia cells
by Bayati, Samaneh and Bashash, Davood and Ahmadian, Shahin and Safaroghli-Azar, Ava and Alimoghaddam, Kamran and Ghavamzadeh, Ardeshir and Ghaffari, Seyed H
European Journal of Pharmacology, ISSN 0014-2999, 2016, Volume 791, pp. 274 - 283
Increasing number of genetic and cancer biology studies indicated a prominent role for tachykinin NK receptor (NK R) in cancer cell growth and survival.... 
Aprepitant | receptor | Acute lymphoblastic leukemia | Nalm-6 cells | Tachykinin NK | P53
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Inhibition of tachykinin NK1 receptor using aprepitant induces apoptotic cell death and G1 arrest through Aktip53 axis in pre-B acute lymphoblastic leukemia cells
by Bayati, S and Bashash, D and Ahmadian, S and Safaroghli-Azar, A and Alimoghaddam, K and Ghavamzadeh, A and Ghaffari, SH
EUROPEAN JOURNAL OF PHARMACOLOGY, ISSN 0014-2999, 11/2016, Volume 791, pp. 274 - 283
Increasing number of genetic and cancer biology studies indicated a prominent role for tachykinin NK1 receptor (Will) in cancer cell growth and survival.... 
Aprepitant | TARGET | ANTAGONIST APREPITANT | NK-1 RECEPTOR | NEUROKININ-1 RECEPTOR | P53 | Tachykinin NK1 receptor | MELANOMA | Acute lymphoblastic leukemia | alm-6 cells | ANTITUMOR ACTION | GROWTH | PHARMACOLOGY & PHARMACY | P53 N | NF-KAPPA-B | EXPRESSION
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Aprepitant for the prevention of chemotherapy‐induced nausea and vomiting in paediatric subjects: An analysis by age group
by Kang, Hyoung Jin and Loftus, Susan and DiCristina, Cara and Green, Stuart and Pong, Annpey and Zwaan, Christian Michel
Pediatric Blood & Cancer, ISSN 1545-5009, 10/2018, Volume 65, Issue 10, pp. e27273 - n/a
Background This was a subgroup analysis of age group, dexamethasone use, and very highly emetogenic chemotherapy (VHEC) use from a randomised, multicentre,... 
paediatrics | adolescent | aprepitant | cancer | anti‐emetics | child | anti-emetics | ANTAGONIST APREPITANT | EFFICACY | ONCOLOGY | TOLERABILITY | DOUBLE-BLIND | PEDIATRICS | PLACEBO-CONTROLLED TRIAL | HEMATOLOGY | Prevention | Pediatrics | Chemotherapy | Dexamethasone | Gastrointestinal agents | Analysis | Nausea | Cancer | Vomiting | Secondary analysis | Age | Subgroups
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text Preparation of Aprepitant nanoparticles (efficient drug for coping with the effects of cancer treatment) by rapid expansion of supercritical solution with solid cosolvent (RESS-SC)
by Sodeifian, Gholamhossein and Sajadian, Seyed Ali and Daneshyan, Sahar
The Journal of Supercritical Fluids, ISSN 0896-8446, 10/2018, Volume 140, pp. 72 - 84
To improve dissolution properties of aprepitant (APR) as a poorly water-soluble drug, Rapid Expansion of Supercritical Solution with Solid Cosolvent (RESS-SC)... 
Nanoparticles | Aprepitant (chemotherapy drug) | Anticancer drug | Dissolution rate enhancement | Solubility | RESS-SC | CHEMISTRY, PHYSICAL | PARTICLE FORMATION | SOLUBILITY MEASUREMENT | ENGINEERING, CHEMICAL | HOMOGENEOUS NUCLEATION | SALICYLIC-ACID | DISSOLUTION | MICRONIZATION | OPTIMIZATION | ESSENTIAL OIL EXTRACTION | CARBON-DIOXIDE | FLUID EXTRACTION | Aprepitant | Chemotherapy | Nanotechnology | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text Placebo-controlled, double-blinded phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3 with combined neurokinin-1 receptor antagonist and palonosetron in high-emetogenic chemotherapy
by Ito, Yuka and Tsuda, Takashi and Minatogawa, Hiroko and Kano, Sayaka and Sakamaki, Kentaro and Ando, Masahiko and Tsugawa, Koichiro and Kojima, Yasuyuki and Furuya, Naoki and Matsuzaki, Kunihiro and Fukuda, Mamoru and Sugae, Sadatoshi and Ohta, Ichiro and Arioka, Hitoshi and Tokuda, Yutaka and Narui, Kazutaka and Tsuboya, Ayako and Suda, Takashi and Morita, Satoshi and Boku, Narikazu and Yamanaka, Takeharu and Nakajima, Takako Eguchi
Journal of Clinical Oncology, ISSN 0732-183X, 04/2018, Volume 36, Issue 10, pp. 1000 - 1006
PurposeWe evaluated the noninferiority of dexamethasone (DEX) on day 1, with sparing on days 2 and 3, combined with neurokinin-1 receptor antagonist (NK1-RA)... 
INDUCED NAUSEA | GUIDELINE UPDATE | NETUPITANT | CONTROLLED TRIAL | CANCER-PATIENTS | EFFICACY | ONCOLOGY | PREVENTION | APREPITANT | FIXED-DOSE COMBINATION
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.